- Home
- PROK vs PTHL Comparison
PROK vs PTHL Comparison
Compare PROK & PTHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- PTHL
- Stock Information
- Founded
- PROK 2015
- PTHL 1998
- Country
- PROK United States
- PTHL China
- Employees
- PROK N/A
- PTHL N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- PTHL
- Sector
- PROK Health Care
- PTHL
- Exchange
- PROK Nasdaq
- PTHL Nasdaq
- Market Cap
- PROK 85.5M
- PTHL 85.4M
- IPO Year
- PROK N/A
- PTHL 2024
- Fundamental
- Price
- PROK $3.27
- PTHL $21.97
- Analyst Decision
- PROK Buy
- PTHL
- Analyst Count
- PROK 5
- PTHL 0
- Target Price
- PROK $6.25
- PTHL N/A
- AVG Volume (30 Days)
- PROK 37.1M
- PTHL 1.7M
- Earning Date
- PROK 08-08-2025
- PTHL 02-11-2025
- Dividend Yield
- PROK N/A
- PTHL N/A
- EPS Growth
- PROK N/A
- PTHL N/A
- EPS
- PROK N/A
- PTHL N/A
- Revenue
- PROK $306,000.00
- PTHL $448,196.00
- Revenue This Year
- PROK $85.21
- PTHL N/A
- Revenue Next Year
- PROK N/A
- PTHL N/A
- P/E Ratio
- PROK N/A
- PTHL N/A
- Revenue Growth
- PROK N/A
- PTHL N/A
- 52 Week Low
- PROK $0.46
- PTHL $1.32
- 52 Week High
- PROK $7.13
- PTHL $28.77
- Technical
- Relative Strength Index (RSI)
- PROK 62.08
- PTHL N/A
- Support Level
- PROK $3.17
- PTHL N/A
- Resistance Level
- PROK $4.05
- PTHL N/A
- Average True Range (ATR)
- PROK 1.00
- PTHL 0.00
- MACD
- PROK 0.13
- PTHL 0.00
- Stochastic Oscillator
- PROK 43.10
- PTHL 0.00
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.